Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Carol A. Pollock et al.|New England Journal of Medicine|2019Cited by 6k
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)Charles A. Herzog, Eberhard Ritz, Richard Asinger et al.|Kidney International|2011Cited by 925
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisBrendon L. Neuen, Meg Jardine, T. Kue Young et al.|The Lancet Diabetes & Endocrinology|2019Cited by 870
Chronic Kidney Disease and Coronary Artery DiseaseMark J. Sarnak, Rukshana Shroff, Kerstin Amann et al.|Journal of the American College of Cardiology|2019Cited by 716
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19Shruti Gupta, Sushrut S. Waikar, Wei Wang et al.|JAMA Internal Medicine|2020Cited by 555